Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: A true marker of acute graft-versus-host disease

被引:22
作者
Kami, M [1 ]
Matsumura, T [1 ]
Tanaka, Y [1 ]
Mikami, Y [1 ]
Miyakoshi, S [1 ]
Ueyama, J [1 ]
Morinaga, S [1 ]
Mori, S [1 ]
Machida, U [1 ]
Kanda, Y [1 ]
Chiba, S [1 ]
Sakamaki, H [1 ]
Hirai, H [1 ]
Muto, Y [1 ]
机构
[1] Toranomon Gen Hosp, Dept Hematol, Minato Ku, Tokyo 1058470, Japan
关键词
soluble interleukin-2 receptor; acute graft-versus-host disease; allogeneic bone marrow transplantation; autologous peripheral blood stem cell transplantation; engraftment;
D O I
10.3109/10428190009059272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To examine whether serum levels of soluble interleukin-2 receptor (sIL-2R) may be a good marker of acute graft-versus-host disease (aGVHD), they were determined weekly in 56 patients receiving bone marrow transplantation (BMT). Because of wide variation in the pre-transplant sIL-2R. levels (from 135 to 1918 IU/ml), we used a sIL-2R index in this study by comparing the pr:ak levels with the pre-transplant levels. In agreement with previous reports, there was a significant correlation between the grade of aGVHD and the maximal sIL-2R index. The maximal sIL-2R index was 4.66 in patients with grade I to IV aGVHD, whereas it was 2.68 in patients without GVHD. This marker may be useful for monitoring the status of aGVHD. However, it was interesting that sIL-2R levels were elevated from the time of transplantation until the third week even in patients without GVHD or those who received autologous transplantation. Until the third week, no significant differences were observed in sIL-2R index between these patients and those who developed aGVHD during their clinical courses. After the fourth week, a higher sIL-2R index was observed in patients with aGVHD than in the other patients. Some factors other than GVHD contribute to the elevation of serum sIL-2R levels, and we: should recognize the limitations of the measurement of this cytokine.
引用
收藏
页码:533 / 540
页数:8
相关论文
共 26 条
  • [1] ANTIN JH, 1992, BLOOD, V80, P2964
  • [2] CYTOKINE DYSREGULATION IN CHRONIC GRAFT-VERSUS-HOST DISEASE
    BARAK, V
    LEVISCHAFFER, F
    NISMAN, B
    NAGLER, A
    [J]. LEUKEMIA & LYMPHOMA, 1995, 17 (1-2) : 169 - 173
  • [3] SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN CYTOMEGALOVIRUS DISEASE AND GRAFT-VERSUS-HOST DISEASE AFTER T-LYMPHOCYTE DEPLETED BONE-MARROW TRANSPLANTATION FOR HEMATOLOGICAL NEOPLASIAS
    ENGELHARD, D
    NAGLER, A
    SINGER, R
    BARAK, V
    [J]. LEUKEMIA & LYMPHOMA, 1994, 12 (3-4) : 273 - 280
  • [4] Cytokine inhibitors and graft-versus-host disease
    Ferrara, JLM
    [J]. BONE MARROW TRANSPLANTATION: FOUNDATIONS FOR THE 21ST CENTURY, 1995, 770 : 227 - 236
  • [5] Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation
    Foley, R
    Couban, S
    Walker, I
    Greene, K
    Chen, CS
    Messner, H
    Gauldie, J
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (08) : 769 - 773
  • [6] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
    GLUCKSBERG, H
    STORB, R
    FEFER, A
    BUCKNER, CD
    NEIMAN, PE
    CLIFT, RA
    LERNER, KG
    THOMAS, ED
    [J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304
  • [7] Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD
    Grimm, J
    Zeller, W
    Zander, AR
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (01) : 29 - 32
  • [8] JADUS MR, 1992, BONE MARROW TRANSPL, V10, P1
  • [9] JOSIMOVIC-ALASEVIC O, 1988, Clinical and Experimental Immunology, V72, P249
  • [10] Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease
    Kobayashi, S
    Imamura, M
    Hashino, S
    Tanaka, J
    Asaka, M
    [J]. LEUKEMIA & LYMPHOMA, 1997, 28 (1-2) : 159 - 169